Enhancing Cisplatin Efficacy with Low Toxicity in Solid Breast Cancer Cells Using pH-Charge-Reversal Sericin-Based Nanocarriers: Development, Characterization, and In Vitro Biological Assessment Article Swipe
Kiana Bahremand
,
Faranak Aghaz
,
Kiumars Bahrami
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1021/acsomega.3c09361
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1021/acsomega.3c09361
Platinum-based chemotherapeutic agents are widely employed in cancer treatment because of their effectiveness in targeting DNA. However, this indiscriminate action often affects both cancerous and normal cells, leading to severe side effects and highlighting the need for innovative approaches in achieving precise drug delivery. Nanotechnology presents a promising avenue for addressing these challenges. Protein-based nanocarriers exhibit promising capabilities in the realm of cancer drug delivery with silk sericin nanoparticles standing out as a leading contender. This investigation focuses on creating a sericin-based nanocarrier (SNC) featuring surface charge reversal designed to effectively transport cisplatin (Cispt-SNC) into MCF-7 breast cancer cells. Utilizing AutoDock4.2, our molecular docking analyses identified key amino acids and revealed distinctive conformational clusters, providing insights into the drug-protein interaction landscape and highlighting the potential of sericin as a carrier for controlled drug release. The careful optimization and fabrication of sericin as the carrier material were achieved through flash nanoprecipitation, a straightforward and reproducible method that is devoid of intricate equipment. The physicochemical properties of SNCs and Cispt-SNCs, particularly concerning size, surface charge, and morphology, were evaluated using dynamic light scattering (DLS) and scanning electron microscopy (SEM). Chemical and conformational analyses of the nanocarriers were conducted using Fourier-transform infrared spectroscopy (FTIR) and circular dichroism (CD), and elemental composition analysis was performed through energy-dispersive X-ray spectroscopy (EDX). This approach aimed to achieve the smallest nanoparticle size for Cispt-SNCs (180 nm) and high drug encapsulation efficiency (84%) at an optimal sericin concentration of 0.1% (w/v), maintaining a negative net charge at a physiological pH (7.4). Cellular uptake and cytotoxicity were investigated in MCF-7 breast cancer cells. SNCs demonstrated stability and exhibited a pH-dependent drug release behavior, aligning with the mildly acidic tumor microenvironment (pH 6.0-7.0). Efficient cellular uptake of Cispt-SNC, along with DNA fragmentation and chromatin condensation, was found at pH 6, leading to cell apoptosis. These results collectively indicate the potential of SNCs for achieving controlled drug release in a tumor-specific context. Our in vitro studies reveal the cytotoxicity of both cisplatin and Cispt-SNCs on MCF-7 cells. Cisplatin significantly reduced cell viability at 10 μM concentration (IC50), and the unique combination of sericin and cisplatin showcased enhanced cell viability compared to cisplatin alone, suggesting that controlled drug release is indicated by a gradient decrease in cell viability and highlighting SNCs as promising carriers. The study underscores the promise of protein-based nanocarriers in advancing targeted drug delivery for cancer therapy.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1021/acsomega.3c09361
- https://pubs.acs.org/doi/pdf/10.1021/acsomega.3c09361
- OA Status
- gold
- Cited By
- 10
- References
- 92
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4392682370
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4392682370Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1021/acsomega.3c09361Digital Object Identifier
- Title
-
Enhancing Cisplatin Efficacy with Low Toxicity in Solid Breast Cancer Cells Using pH-Charge-Reversal Sericin-Based Nanocarriers: Development, Characterization, and In Vitro Biological AssessmentWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-03-12Full publication date if available
- Authors
-
Kiana Bahremand, Faranak Aghaz, Kiumars BahramiList of authors in order
- Landing page
-
https://doi.org/10.1021/acsomega.3c09361Publisher landing page
- PDF URL
-
https://pubs.acs.org/doi/pdf/10.1021/acsomega.3c09361Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://pubs.acs.org/doi/pdf/10.1021/acsomega.3c09361Direct OA link when available
- Concepts
-
Nanocarriers, Cisplatin, Sericin, Toxicity, In vitro, Characterization (materials science), Breast cancer, Pharmacology, Chemistry, Nanotechnology, Medicine, Oncology, Materials science, Cancer, Internal medicine, Chemotherapy, Biochemistry, Drug, Pathology, Alternative medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
10Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 8, 2024: 2Per-year citation counts (last 5 years)
- References (count)
-
92Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4392682370 |
|---|---|
| doi | https://doi.org/10.1021/acsomega.3c09361 |
| ids.doi | https://doi.org/10.1021/acsomega.3c09361 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38560009 |
| ids.openalex | https://openalex.org/W4392682370 |
| fwci | 3.51003249 |
| type | article |
| title | Enhancing Cisplatin Efficacy with Low Toxicity in Solid Breast Cancer Cells Using pH-Charge-Reversal Sericin-Based Nanocarriers: Development, Characterization, and In Vitro Biological Assessment |
| biblio.issue | 12 |
| biblio.volume | 9 |
| biblio.last_page | 14032 |
| biblio.first_page | 14017 |
| grants[0].funder | https://openalex.org/F4320323227 |
| grants[0].award_id | |
| grants[0].funder_display_name | Kermanshah University of Medical Sciences |
| topics[0].id | https://openalex.org/T10063 |
| topics[0].field.id | https://openalex.org/fields/25 |
| topics[0].field.display_name | Materials Science |
| topics[0].score | 0.9990000128746033 |
| topics[0].domain.id | https://openalex.org/domains/3 |
| topics[0].domain.display_name | Physical Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2502 |
| topics[0].subfield.display_name | Biomaterials |
| topics[0].display_name | Nanoparticle-Based Drug Delivery |
| topics[1].id | https://openalex.org/T10725 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9987999796867371 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | RNA Interference and Gene Delivery |
| topics[2].id | https://openalex.org/T11686 |
| topics[2].field.id | https://openalex.org/fields/25 |
| topics[2].field.display_name | Materials Science |
| topics[2].score | 0.996999979019165 |
| topics[2].domain.id | https://openalex.org/domains/3 |
| topics[2].domain.display_name | Physical Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2507 |
| topics[2].subfield.display_name | Polymers and Plastics |
| topics[2].display_name | Dendrimers and Hyperbranched Polymers |
| funders[0].id | https://openalex.org/F4320323227 |
| funders[0].ror | https://ror.org/05vspf741 |
| funders[0].display_name | Kermanshah University of Medical Sciences |
| is_xpac | False |
| apc_list.value | 1685 |
| apc_list.currency | USD |
| apc_list.value_usd | 1685 |
| apc_paid.value | 1685 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 1685 |
| concepts[0].id | https://openalex.org/C18150654 |
| concepts[0].level | 3 |
| concepts[0].score | 0.834975004196167 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q17153796 |
| concepts[0].display_name | Nanocarriers |
| concepts[1].id | https://openalex.org/C2778239845 |
| concepts[1].level | 3 |
| concepts[1].score | 0.6724882125854492 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q412415 |
| concepts[1].display_name | Cisplatin |
| concepts[2].id | https://openalex.org/C206767735 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6388257741928101 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q2983186 |
| concepts[2].display_name | Sericin |
| concepts[3].id | https://openalex.org/C29730261 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5650214552879333 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q274160 |
| concepts[3].display_name | Toxicity |
| concepts[4].id | https://openalex.org/C202751555 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5189682841300964 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q221681 |
| concepts[4].display_name | In vitro |
| concepts[5].id | https://openalex.org/C2780841128 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5079823136329651 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q5073781 |
| concepts[5].display_name | Characterization (materials science) |
| concepts[6].id | https://openalex.org/C530470458 |
| concepts[6].level | 3 |
| concepts[6].score | 0.47955700755119324 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q128581 |
| concepts[6].display_name | Breast cancer |
| concepts[7].id | https://openalex.org/C98274493 |
| concepts[7].level | 1 |
| concepts[7].score | 0.41378918290138245 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[7].display_name | Pharmacology |
| concepts[8].id | https://openalex.org/C185592680 |
| concepts[8].level | 0 |
| concepts[8].score | 0.38964542746543884 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[8].display_name | Chemistry |
| concepts[9].id | https://openalex.org/C171250308 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3515673577785492 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q11468 |
| concepts[9].display_name | Nanotechnology |
| concepts[10].id | https://openalex.org/C71924100 |
| concepts[10].level | 0 |
| concepts[10].score | 0.3458442986011505 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[10].display_name | Medicine |
| concepts[11].id | https://openalex.org/C143998085 |
| concepts[11].level | 1 |
| concepts[11].score | 0.3421502709388733 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[11].display_name | Oncology |
| concepts[12].id | https://openalex.org/C192562407 |
| concepts[12].level | 0 |
| concepts[12].score | 0.3056088984012604 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q228736 |
| concepts[12].display_name | Materials science |
| concepts[13].id | https://openalex.org/C121608353 |
| concepts[13].level | 2 |
| concepts[13].score | 0.29400157928466797 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[13].display_name | Cancer |
| concepts[14].id | https://openalex.org/C126322002 |
| concepts[14].level | 1 |
| concepts[14].score | 0.1965063214302063 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[14].display_name | Internal medicine |
| concepts[15].id | https://openalex.org/C2776694085 |
| concepts[15].level | 2 |
| concepts[15].score | 0.15094172954559326 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[15].display_name | Chemotherapy |
| concepts[16].id | https://openalex.org/C55493867 |
| concepts[16].level | 1 |
| concepts[16].score | 0.1494615077972412 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[16].display_name | Biochemistry |
| concepts[17].id | https://openalex.org/C2780035454 |
| concepts[17].level | 2 |
| concepts[17].score | 0.10833442211151123 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q8386 |
| concepts[17].display_name | Drug |
| concepts[18].id | https://openalex.org/C142724271 |
| concepts[18].level | 1 |
| concepts[18].score | 0.06409889459609985 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[18].display_name | Pathology |
| concepts[19].id | https://openalex.org/C204787440 |
| concepts[19].level | 2 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q188504 |
| concepts[19].display_name | Alternative medicine |
| keywords[0].id | https://openalex.org/keywords/nanocarriers |
| keywords[0].score | 0.834975004196167 |
| keywords[0].display_name | Nanocarriers |
| keywords[1].id | https://openalex.org/keywords/cisplatin |
| keywords[1].score | 0.6724882125854492 |
| keywords[1].display_name | Cisplatin |
| keywords[2].id | https://openalex.org/keywords/sericin |
| keywords[2].score | 0.6388257741928101 |
| keywords[2].display_name | Sericin |
| keywords[3].id | https://openalex.org/keywords/toxicity |
| keywords[3].score | 0.5650214552879333 |
| keywords[3].display_name | Toxicity |
| keywords[4].id | https://openalex.org/keywords/in-vitro |
| keywords[4].score | 0.5189682841300964 |
| keywords[4].display_name | In vitro |
| keywords[5].id | https://openalex.org/keywords/characterization |
| keywords[5].score | 0.5079823136329651 |
| keywords[5].display_name | Characterization (materials science) |
| keywords[6].id | https://openalex.org/keywords/breast-cancer |
| keywords[6].score | 0.47955700755119324 |
| keywords[6].display_name | Breast cancer |
| keywords[7].id | https://openalex.org/keywords/pharmacology |
| keywords[7].score | 0.41378918290138245 |
| keywords[7].display_name | Pharmacology |
| keywords[8].id | https://openalex.org/keywords/chemistry |
| keywords[8].score | 0.38964542746543884 |
| keywords[8].display_name | Chemistry |
| keywords[9].id | https://openalex.org/keywords/nanotechnology |
| keywords[9].score | 0.3515673577785492 |
| keywords[9].display_name | Nanotechnology |
| keywords[10].id | https://openalex.org/keywords/medicine |
| keywords[10].score | 0.3458442986011505 |
| keywords[10].display_name | Medicine |
| keywords[11].id | https://openalex.org/keywords/oncology |
| keywords[11].score | 0.3421502709388733 |
| keywords[11].display_name | Oncology |
| keywords[12].id | https://openalex.org/keywords/materials-science |
| keywords[12].score | 0.3056088984012604 |
| keywords[12].display_name | Materials science |
| keywords[13].id | https://openalex.org/keywords/cancer |
| keywords[13].score | 0.29400157928466797 |
| keywords[13].display_name | Cancer |
| keywords[14].id | https://openalex.org/keywords/internal-medicine |
| keywords[14].score | 0.1965063214302063 |
| keywords[14].display_name | Internal medicine |
| keywords[15].id | https://openalex.org/keywords/chemotherapy |
| keywords[15].score | 0.15094172954559326 |
| keywords[15].display_name | Chemotherapy |
| keywords[16].id | https://openalex.org/keywords/biochemistry |
| keywords[16].score | 0.1494615077972412 |
| keywords[16].display_name | Biochemistry |
| keywords[17].id | https://openalex.org/keywords/drug |
| keywords[17].score | 0.10833442211151123 |
| keywords[17].display_name | Drug |
| keywords[18].id | https://openalex.org/keywords/pathology |
| keywords[18].score | 0.06409889459609985 |
| keywords[18].display_name | Pathology |
| language | en |
| locations[0].id | doi:10.1021/acsomega.3c09361 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210239500 |
| locations[0].source.issn | 2470-1343 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2470-1343 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | ACS Omega |
| locations[0].source.host_organization | https://openalex.org/P4310320006 |
| locations[0].source.host_organization_name | American Chemical Society |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320006 |
| locations[0].license | |
| locations[0].pdf_url | https://pubs.acs.org/doi/pdf/10.1021/acsomega.3c09361 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | ACS Omega |
| locations[0].landing_page_url | https://doi.org/10.1021/acsomega.3c09361 |
| locations[1].id | pmid:38560009 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | ACS omega |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38560009 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:10976391 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | ACS Omega |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/10976391 |
| locations[3].id | pmh:oai:doaj.org/article:499033955f154e14b94ad7b47f357813 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].source.host_organization_lineage | |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | ACS Omega, Vol 9, Iss 12, Pp 14017-14032 (2024) |
| locations[3].landing_page_url | https://doaj.org/article/499033955f154e14b94ad7b47f357813 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5094123914 |
| authorships[0].author.orcid | https://orcid.org/0009-0003-0314-961X |
| authorships[0].author.display_name | Kiana Bahremand |
| authorships[0].countries | IR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I39642139 |
| authorships[0].affiliations[0].raw_affiliation_string | Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran |
| authorships[0].institutions[0].id | https://openalex.org/I39642139 |
| authorships[0].institutions[0].ror | https://ror.org/05vspf741 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I39642139 |
| authorships[0].institutions[0].country_code | IR |
| authorships[0].institutions[0].display_name | Kermanshah University of Medical Sciences |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Kiana Bahremand |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran |
| authorships[1].author.id | https://openalex.org/A5047823823 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-7311-4071 |
| authorships[1].author.display_name | Faranak Aghaz |
| authorships[1].countries | IR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I39642139 |
| authorships[1].affiliations[0].raw_affiliation_string | Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran |
| authorships[1].institutions[0].id | https://openalex.org/I39642139 |
| authorships[1].institutions[0].ror | https://ror.org/05vspf741 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I39642139 |
| authorships[1].institutions[0].country_code | IR |
| authorships[1].institutions[0].display_name | Kermanshah University of Medical Sciences |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Faranak Aghaz |
| authorships[1].is_corresponding | True |
| authorships[1].raw_affiliation_strings | Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran |
| authorships[2].author.id | https://openalex.org/A5040661511 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-9229-0890 |
| authorships[2].author.display_name | Kiumars Bahrami |
| authorships[2].countries | IR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I1187138 |
| authorships[2].affiliations[0].raw_affiliation_string | Nanoscience and Nanotechnology Research Center (NNRC), Razi University, Kermanshah 67144-14971, Iran |
| authorships[2].institutions[0].id | https://openalex.org/I1187138 |
| authorships[2].institutions[0].ror | https://ror.org/02ynb0474 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I1187138 |
| authorships[2].institutions[0].country_code | IR |
| authorships[2].institutions[0].display_name | Razi University |
| authorships[2].author_position | last |
| authorships[2].raw_author_name | Kiumars Bahrami |
| authorships[2].is_corresponding | True |
| authorships[2].raw_affiliation_strings | Nanoscience and Nanotechnology Research Center (NNRC), Razi University, Kermanshah 67144-14971, Iran |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://pubs.acs.org/doi/pdf/10.1021/acsomega.3c09361 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2024-03-13T00:00:00 |
| display_name | Enhancing Cisplatin Efficacy with Low Toxicity in Solid Breast Cancer Cells Using pH-Charge-Reversal Sericin-Based Nanocarriers: Development, Characterization, and In Vitro Biological Assessment |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T06:51:31.235846 |
| primary_topic.id | https://openalex.org/T10063 |
| primary_topic.field.id | https://openalex.org/fields/25 |
| primary_topic.field.display_name | Materials Science |
| primary_topic.score | 0.9990000128746033 |
| primary_topic.domain.id | https://openalex.org/domains/3 |
| primary_topic.domain.display_name | Physical Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2502 |
| primary_topic.subfield.display_name | Biomaterials |
| primary_topic.display_name | Nanoparticle-Based Drug Delivery |
| related_works | https://openalex.org/W2209694101, https://openalex.org/W2046561857, https://openalex.org/W4236457018, https://openalex.org/W2375260602, https://openalex.org/W2555349355, https://openalex.org/W2217850601, https://openalex.org/W2394206756, https://openalex.org/W2109067574, https://openalex.org/W2036120581, https://openalex.org/W2506029393 |
| cited_by_count | 10 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 8 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 2 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1021/acsomega.3c09361 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210239500 |
| best_oa_location.source.issn | 2470-1343 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2470-1343 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | ACS Omega |
| best_oa_location.source.host_organization | https://openalex.org/P4310320006 |
| best_oa_location.source.host_organization_name | American Chemical Society |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320006 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://pubs.acs.org/doi/pdf/10.1021/acsomega.3c09361 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | ACS Omega |
| best_oa_location.landing_page_url | https://doi.org/10.1021/acsomega.3c09361 |
| primary_location.id | doi:10.1021/acsomega.3c09361 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210239500 |
| primary_location.source.issn | 2470-1343 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2470-1343 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | ACS Omega |
| primary_location.source.host_organization | https://openalex.org/P4310320006 |
| primary_location.source.host_organization_name | American Chemical Society |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320006 |
| primary_location.license | |
| primary_location.pdf_url | https://pubs.acs.org/doi/pdf/10.1021/acsomega.3c09361 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | ACS Omega |
| primary_location.landing_page_url | https://doi.org/10.1021/acsomega.3c09361 |
| publication_date | 2024-03-12 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W4307298867, https://openalex.org/W4315754639, https://openalex.org/W3026799953, https://openalex.org/W1571365882, https://openalex.org/W3081020835, https://openalex.org/W4386127756, https://openalex.org/W2158305374, https://openalex.org/W2012108057, https://openalex.org/W4315798454, https://openalex.org/W1987604182, https://openalex.org/W2938216505, https://openalex.org/W2078144803, https://openalex.org/W2084492467, https://openalex.org/W2035690443, https://openalex.org/W2890167612, https://openalex.org/W1246937494, https://openalex.org/W4205452973, https://openalex.org/W2562544977, https://openalex.org/W2897440482, https://openalex.org/W4206464318, https://openalex.org/W2072818864, https://openalex.org/W1990440588, https://openalex.org/W2041998484, https://openalex.org/W1937091029, https://openalex.org/W4323318251, https://openalex.org/W2042509194, https://openalex.org/W2080411925, https://openalex.org/W2026799007, https://openalex.org/W2151132896, https://openalex.org/W2025607183, https://openalex.org/W2064175793, https://openalex.org/W2742287127, https://openalex.org/W1974825099, https://openalex.org/W3158343199, https://openalex.org/W2739999456, https://openalex.org/W2037312364, https://openalex.org/W2153191110, https://openalex.org/W2104812418, https://openalex.org/W2105668062, https://openalex.org/W4383619738, https://openalex.org/W2040586215, https://openalex.org/W3199250360, https://openalex.org/W2805756697, https://openalex.org/W4379987079, https://openalex.org/W4294723689, https://openalex.org/W2586464879, https://openalex.org/W2086725441, https://openalex.org/W2571390968, https://openalex.org/W2150900483, https://openalex.org/W1979113720, https://openalex.org/W2597805119, https://openalex.org/W1817316342, https://openalex.org/W2071461425, https://openalex.org/W4200341696, https://openalex.org/W2010029243, https://openalex.org/W2571978672, https://openalex.org/W3028279197, https://openalex.org/W3047041100, https://openalex.org/W2920020242, https://openalex.org/W2944564217, https://openalex.org/W2517683463, https://openalex.org/W2282989227, https://openalex.org/W2795139701, https://openalex.org/W2012867962, https://openalex.org/W3001723661, https://openalex.org/W4281774178, https://openalex.org/W4224231129, https://openalex.org/W3184436107, https://openalex.org/W2973395988, https://openalex.org/W2951172768, https://openalex.org/W1515077347, https://openalex.org/W1978635875, https://openalex.org/W2064093384, https://openalex.org/W2940562470, https://openalex.org/W2053311966, https://openalex.org/W2592289528, https://openalex.org/W2106101402, https://openalex.org/W1963675633, https://openalex.org/W2522107642, https://openalex.org/W2147807319, https://openalex.org/W2965915193, https://openalex.org/W2165031969, https://openalex.org/W2519101378, https://openalex.org/W2016129077, https://openalex.org/W4207084410, https://openalex.org/W3125204155, https://openalex.org/W2035242795, https://openalex.org/W3020575323, https://openalex.org/W4213149762, https://openalex.org/W4207040434, https://openalex.org/W2027809986, https://openalex.org/W3036910226 |
| referenced_works_count | 92 |
| abstract_inverted_index.a | 46, 72, 80, 128, 150, 244, 249, 269, 318, 370 |
| abstract_inverted_index.10 | 342 |
| abstract_inverted_index.6, | 299 |
| abstract_inverted_index.an | 236 |
| abstract_inverted_index.as | 71, 127, 141, 379 |
| abstract_inverted_index.at | 235, 248, 297, 341 |
| abstract_inverted_index.by | 369 |
| abstract_inverted_index.in | 6, 13, 39, 58, 259, 317, 373, 390 |
| abstract_inverted_index.is | 156, 367 |
| abstract_inverted_index.of | 10, 61, 125, 139, 158, 164, 191, 240, 286, 310, 328, 350, 387 |
| abstract_inverted_index.on | 78, 333 |
| abstract_inverted_index.pH | 251, 298 |
| abstract_inverted_index.to | 28, 89, 219, 301, 359 |
| abstract_inverted_index.(pH | 281 |
| abstract_inverted_index.DNA | 290 |
| abstract_inverted_index.Our | 321 |
| abstract_inverted_index.The | 134, 161, 382 |
| abstract_inverted_index.and | 24, 32, 109, 121, 137, 152, 166, 173, 182, 188, 201, 205, 229, 255, 267, 292, 331, 346, 352, 376 |
| abstract_inverted_index.are | 3 |
| abstract_inverted_index.for | 36, 49, 130, 225, 312, 395 |
| abstract_inverted_index.key | 106 |
| abstract_inverted_index.net | 246 |
| abstract_inverted_index.nm) | 228 |
| abstract_inverted_index.our | 101 |
| abstract_inverted_index.out | 70 |
| abstract_inverted_index.the | 34, 59, 117, 123, 142, 192, 221, 276, 308, 326, 347, 385 |
| abstract_inverted_index.was | 209, 295 |
| abstract_inverted_index.μM | 343 |
| abstract_inverted_index.(180 | 227 |
| abstract_inverted_index.0.1% | 241 |
| abstract_inverted_index.DNA. | 15 |
| abstract_inverted_index.SNCs | 165, 264, 311, 378 |
| abstract_inverted_index.This | 75, 216 |
| abstract_inverted_index.both | 22, 329 |
| abstract_inverted_index.cell | 302, 339, 356, 374 |
| abstract_inverted_index.drug | 42, 63, 132, 231, 271, 315, 365, 393 |
| abstract_inverted_index.high | 230 |
| abstract_inverted_index.into | 94, 116 |
| abstract_inverted_index.need | 35 |
| abstract_inverted_index.side | 30 |
| abstract_inverted_index.silk | 66 |
| abstract_inverted_index.size | 224 |
| abstract_inverted_index.that | 155, 363 |
| abstract_inverted_index.this | 17 |
| abstract_inverted_index.were | 145, 175, 194, 257 |
| abstract_inverted_index.with | 65, 275, 289 |
| abstract_inverted_index.(84%) | 234 |
| abstract_inverted_index.(CD), | 204 |
| abstract_inverted_index.(DLS) | 181 |
| abstract_inverted_index.(SNC) | 83 |
| abstract_inverted_index.<i>in | 322 |
| abstract_inverted_index.MCF-7 | 95, 260, 334 |
| abstract_inverted_index.These | 304 |
| abstract_inverted_index.X-ray | 213 |
| abstract_inverted_index.acids | 108 |
| abstract_inverted_index.aimed | 218 |
| abstract_inverted_index.along | 288 |
| abstract_inverted_index.amino | 107 |
| abstract_inverted_index.flash | 148 |
| abstract_inverted_index.found | 296 |
| abstract_inverted_index.light | 179 |
| abstract_inverted_index.often | 20 |
| abstract_inverted_index.realm | 60 |
| abstract_inverted_index.size, | 170 |
| abstract_inverted_index.study | 383 |
| abstract_inverted_index.their | 11 |
| abstract_inverted_index.these | 51 |
| abstract_inverted_index.tumor | 279 |
| abstract_inverted_index.using | 177, 196 |
| abstract_inverted_index.(7.4). | 252 |
| abstract_inverted_index.(EDX). | 215 |
| abstract_inverted_index.(FTIR) | 200 |
| abstract_inverted_index.(SEM). | 186 |
| abstract_inverted_index.(w/v), | 242 |
| abstract_inverted_index.acidic | 278 |
| abstract_inverted_index.action | 19 |
| abstract_inverted_index.agents | 2 |
| abstract_inverted_index.alone, | 361 |
| abstract_inverted_index.avenue | 48 |
| abstract_inverted_index.breast | 96, 261 |
| abstract_inverted_index.cancer | 7, 62, 97, 262, 396 |
| abstract_inverted_index.cells, | 26 |
| abstract_inverted_index.cells. | 98, 263, 335 |
| abstract_inverted_index.charge | 86, 247 |
| abstract_inverted_index.devoid | 157 |
| abstract_inverted_index.method | 154 |
| abstract_inverted_index.mildly | 277 |
| abstract_inverted_index.normal | 25 |
| abstract_inverted_index.reveal | 325 |
| abstract_inverted_index.severe | 29 |
| abstract_inverted_index.unique | 348 |
| abstract_inverted_index.uptake | 254, 285 |
| abstract_inverted_index.widely | 4 |
| abstract_inverted_index.achieve | 220 |
| abstract_inverted_index.affects | 21 |
| abstract_inverted_index.because | 9 |
| abstract_inverted_index.careful | 135 |
| abstract_inverted_index.carrier | 129, 143 |
| abstract_inverted_index.charge, | 172 |
| abstract_inverted_index.docking | 103 |
| abstract_inverted_index.dynamic | 178 |
| abstract_inverted_index.effects | 31 |
| abstract_inverted_index.exhibit | 55 |
| abstract_inverted_index.focuses | 77 |
| abstract_inverted_index.leading | 27, 73, 300 |
| abstract_inverted_index.optimal | 237 |
| abstract_inverted_index.precise | 41 |
| abstract_inverted_index.promise | 386 |
| abstract_inverted_index.reduced | 338 |
| abstract_inverted_index.release | 272, 316, 366 |
| abstract_inverted_index.results | 305 |
| abstract_inverted_index.sericin | 67, 126, 140, 238, 351 |
| abstract_inverted_index.studies | 324 |
| abstract_inverted_index.surface | 85, 171 |
| abstract_inverted_index.through | 147, 211 |
| abstract_inverted_index.Cellular | 253 |
| abstract_inverted_index.Chemical | 187 |
| abstract_inverted_index.However, | 16 |
| abstract_inverted_index.achieved | 146 |
| abstract_inverted_index.aligning | 274 |
| abstract_inverted_index.analyses | 104, 190 |
| abstract_inverted_index.analysis | 208 |
| abstract_inverted_index.approach | 217 |
| abstract_inverted_index.cellular | 284 |
| abstract_inverted_index.circular | 202 |
| abstract_inverted_index.compared | 358 |
| abstract_inverted_index.context. | 320 |
| abstract_inverted_index.creating | 79 |
| abstract_inverted_index.decrease | 372 |
| abstract_inverted_index.delivery | 64, 394 |
| abstract_inverted_index.designed | 88 |
| abstract_inverted_index.electron | 184 |
| abstract_inverted_index.employed | 5 |
| abstract_inverted_index.enhanced | 355 |
| abstract_inverted_index.gradient | 371 |
| abstract_inverted_index.indicate | 307 |
| abstract_inverted_index.infrared | 198 |
| abstract_inverted_index.insights | 115 |
| abstract_inverted_index.material | 144 |
| abstract_inverted_index.negative | 245 |
| abstract_inverted_index.presents | 45 |
| abstract_inverted_index.release. | 133 |
| abstract_inverted_index.revealed | 110 |
| abstract_inverted_index.reversal | 87 |
| abstract_inverted_index.scanning | 183 |
| abstract_inverted_index.smallest | 222 |
| abstract_inverted_index.standing | 69 |
| abstract_inverted_index.targeted | 392 |
| abstract_inverted_index.therapy. | 397 |
| abstract_inverted_index.6.0-7.0). | 282 |
| abstract_inverted_index.Cisplatin | 336 |
| abstract_inverted_index.Efficient | 283 |
| abstract_inverted_index.Utilizing | 99 |
| abstract_inverted_index.achieving | 40, 313 |
| abstract_inverted_index.advancing | 391 |
| abstract_inverted_index.behavior, | 273 |
| abstract_inverted_index.cancerous | 23 |
| abstract_inverted_index.carriers. | 381 |
| abstract_inverted_index.chromatin | 293 |
| abstract_inverted_index.cisplatin | 92, 330, 353, 360 |
| abstract_inverted_index.clusters, | 113 |
| abstract_inverted_index.conducted | 195 |
| abstract_inverted_index.delivery. | 43 |
| abstract_inverted_index.dichroism | 203 |
| abstract_inverted_index.elemental | 206 |
| abstract_inverted_index.evaluated | 176 |
| abstract_inverted_index.exhibited | 268 |
| abstract_inverted_index.featuring | 84 |
| abstract_inverted_index.indicated | 368 |
| abstract_inverted_index.intricate | 159 |
| abstract_inverted_index.landscape | 120 |
| abstract_inverted_index.molecular | 102 |
| abstract_inverted_index.performed | 210 |
| abstract_inverted_index.potential | 124, 309 |
| abstract_inverted_index.promising | 47, 56, 380 |
| abstract_inverted_index.providing | 114 |
| abstract_inverted_index.showcased | 354 |
| abstract_inverted_index.stability | 266 |
| abstract_inverted_index.targeting | 14 |
| abstract_inverted_index.transport | 91 |
| abstract_inverted_index.treatment | 8 |
| abstract_inverted_index.viability | 340, 357, 375 |
| abstract_inverted_index.vitro</i> | 323 |
| abstract_inverted_index.Cispt-SNC, | 287 |
| abstract_inverted_index.Cispt-SNCs | 226, 332 |
| abstract_inverted_index.addressing | 50 |
| abstract_inverted_index.apoptosis. | 303 |
| abstract_inverted_index.approaches | 38 |
| abstract_inverted_index.concerning | 169 |
| abstract_inverted_index.contender. | 74 |
| abstract_inverted_index.controlled | 131, 314, 364 |
| abstract_inverted_index.efficiency | 233 |
| abstract_inverted_index.equipment. | 160 |
| abstract_inverted_index.identified | 105 |
| abstract_inverted_index.innovative | 37 |
| abstract_inverted_index.microscopy | 185 |
| abstract_inverted_index.properties | 163 |
| abstract_inverted_index.scattering | 180 |
| abstract_inverted_index.suggesting | 362 |
| abstract_inverted_index.(Cispt-SNC) | 93 |
| abstract_inverted_index.Cispt-SNCs, | 167 |
| abstract_inverted_index.challenges. | 52 |
| abstract_inverted_index.combination | 349 |
| abstract_inverted_index.composition | 207 |
| abstract_inverted_index.distinctive | 111 |
| abstract_inverted_index.effectively | 90 |
| abstract_inverted_index.fabrication | 138 |
| abstract_inverted_index.interaction | 119 |
| abstract_inverted_index.maintaining | 243 |
| abstract_inverted_index.morphology, | 174 |
| abstract_inverted_index.nanocarrier | 82 |
| abstract_inverted_index.underscores | 384 |
| abstract_inverted_index.AutoDock4.2, | 100 |
| abstract_inverted_index.capabilities | 57 |
| abstract_inverted_index.collectively | 306 |
| abstract_inverted_index.cytotoxicity | 256, 327 |
| abstract_inverted_index.demonstrated | 265 |
| abstract_inverted_index.drug-protein | 118 |
| abstract_inverted_index.highlighting | 33, 122, 377 |
| abstract_inverted_index.investigated | 258 |
| abstract_inverted_index.nanocarriers | 54, 193, 389 |
| abstract_inverted_index.nanoparticle | 223 |
| abstract_inverted_index.optimization | 136 |
| abstract_inverted_index.pH-dependent | 270 |
| abstract_inverted_index.particularly | 168 |
| abstract_inverted_index.reproducible | 153 |
| abstract_inverted_index.spectroscopy | 199, 214 |
| abstract_inverted_index.Protein-based | 53 |
| abstract_inverted_index.concentration | 239, 344 |
| abstract_inverted_index.condensation, | 294 |
| abstract_inverted_index.effectiveness | 12 |
| abstract_inverted_index.encapsulation | 232 |
| abstract_inverted_index.fragmentation | 291 |
| abstract_inverted_index.investigation | 76 |
| abstract_inverted_index.nanoparticles | 68 |
| abstract_inverted_index.physiological | 250 |
| abstract_inverted_index.protein-based | 388 |
| abstract_inverted_index.sericin-based | 81 |
| abstract_inverted_index.significantly | 337 |
| abstract_inverted_index.Nanotechnology | 44 |
| abstract_inverted_index.Platinum-based | 0 |
| abstract_inverted_index.conformational | 112, 189 |
| abstract_inverted_index.indiscriminate | 18 |
| abstract_inverted_index.tumor-specific | 319 |
| abstract_inverted_index.physicochemical | 162 |
| abstract_inverted_index.straightforward | 151 |
| abstract_inverted_index.chemotherapeutic | 1 |
| abstract_inverted_index.microenvironment | 280 |
| abstract_inverted_index.Fourier-transform | 197 |
| abstract_inverted_index.energy-dispersive | 212 |
| abstract_inverted_index.(IC<sub>50</sub>), | 345 |
| abstract_inverted_index.nanoprecipitation, | 149 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 94 |
| corresponding_author_ids | https://openalex.org/A5040661511, https://openalex.org/A5047823823 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 3 |
| corresponding_institution_ids | https://openalex.org/I1187138, https://openalex.org/I39642139 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/16 |
| sustainable_development_goals[0].score | 0.41999998688697815 |
| sustainable_development_goals[0].display_name | Peace, Justice and strong institutions |
| citation_normalized_percentile.value | 0.8700892 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |